Kornimate/medical-research-clean huggingface dataset:
optimization of outpatient surgery at the chum using the leomed telecare platform

Conditions: Surgery--Complications; Patient Satisfaction; Quality of Life

Summary: the main objective of this study is to carry out a medico-economic evaluation of a new platform for outpatient surgical care, by comparing the effectiveness and utility of the deployment of this trajectory on patients and the health system to a control group.

outpatient surgery allows the patient to leave the hospital on the day of their surgery and thus avoid complete hospitalization. there are many advantages to this practice. patients can remain in the comfort of their own home with the support of their family caregivers and the healthcare system can avoid incurring additional hospital costs and redirect these savings to other critical needs. however, despite the advantages of outpatient surgery, the tools and measures currently in place to supervise the preparation before the operation and the follow-up after the operation are suboptimal. following surgery, adverse events such as moderate to severe pain, nausea/vomiting, infection and bleeding from the operative site are very rarely sought out and detected by healthcare facilities. however, these are the main causes of readmissions or emergency consultations for patients. in order to optimize the care offer, the anesthesiology department, the innovation and artificial intelligence center of the chum as well as the quebec telecare platform leomed have joined forces in order to offer, through a health application, follow-up and personalized support for patients undergoing outpatient surgery. the investigators believe that the integration of this platform in the course of care will allow early diagnosis of the main postoperative complications and therefore, prevent calls to the health-info line, emergency room returns, as well as readmissions or unscheduled postoperative consultations. a patient-as-partner approach has been chosen in the initial phase, where 12 patients having had an outpatient surgery less than 6 months ago, will be recruited to test the platform. another 12 patients, scheduled to undergo an outpatient surgery, will test the optimized support and follow up application. their feedback will help to correct and/or improve the platform, if necessary.

Eligibility criteria:
inclusion criteria: * patients over 18 years old undergoing elective outpatient surgery under general or regional anesthesia * internet access for the patient or their caregiver from home * written, oral and spoken comprehension of french or english exclusion criteria: * patient's or caregiver's inability to learn and use digital technologies * conversion of outpatient to inpatient hospitalization on the day of surgery * patient's refusal.
safety study of chimerivax™-je vaccine to prevent japanese encephalitis.

Conditions: Encephalitis; Japanese Encephalitis

Summary: the purpose of this study is to assess whether chimerivax™ je vaccine (a new vaccine to be used for vaccination against japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.


Eligibility criteria:
inclusion criteria: * informed consent obtained from the subject. * aged 18 years or above at screening. * in good general health * subject available for the study duration * for female subjects (of child bearing potential) a negative pregnancy tests at screening and day 0. exclusion criteria: * a history of vaccination against or infection with je. * known or suspected immunodeficiency, use of immunosuppressive or antineoplastic drugs. * history of thymoma, thymic surgery (removal) or myasthenia gravis. * clinically significant abnormalities on laboratory assessment * anaphylaxis or other serious adverse reactions characterised by urticaria or angioedema to foods, hymenoptera (bee family) stings, or drugs including vaccines). * transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the screening visit or up to day 30. * administration of another vaccine or antiviral within 30 days preceding the screening visit or up to day 30. * physical examination indicating any clinically significant medical condition. * oral temperature \>38°c (100.4°f) or acute illness within 3 days prior to inoculation. * intention to travel out of the area for an extended period that may affect the subjects ability to attend clinic visits prior to the study visit up to day 30. * seropositive to hepatitis c virus (hcv) or hiv or positive for hepatitis b surface antigen. * lactation or intended pregnancy in female subjects. * excessive alcohol consumption, drug abuse, significant psychiatric illness. * a known or suspected physiological or structural condition that compromises the integrity of the blood-brain barrier (e.g. cerebrovascular disease, multiple sclerosis, trauma, infection, inflammation of the brain or meninges). * participation in another clinical study within 30 days of the screening visit for this study. * employee of the study site, sponsor or clinical research organization (cro) involved with the management of the study. * any other reasons, which in the investigator's opinion, makes the subject unsuitable to participate in the study.

Keywords: japanese encephalitis encephalitis virus chimerivax™-je vaccine
sensing-ai in patients with long covid (sensing-ai)

Conditions: Post-acute COVID-19 Syndrome

Summary: the retrospective study will be used to develop an artificial intelligence model of risk stratification of physiological and psychological complications arising from the information available in the electronic medical record and first consultation report to support patients and healthcare professionals in better managing the healthcare process for patients diagnosed with long covid.

the stratification of the risk of complications related to persistent covid both physiological and psychological in a personalized way would optimize the cost-effectiveness model for the management of these patients. similarly, the early detection of complications associated with persistent covid in patients belonging to vulnerable groups would improve care times and, therefore, the patient's prognosis. the primary objective for this study is to gather anonymized retrospective data of patients suffering from long covid in order to contribute to the generation of the sensing-ai cohort.

Eligibility criteria:
inclusion criteria: * legal adult * diagnosed of long covid-19 in the last year * with the presence of any of these symptoms: * asthenia (tiredness) * dyspnea * shortness of breath * anxiety * stress * depression * sleep disorder exclusion criteria: * attended to specialized care consultation * was admitted in hospital in the last year due to a problem not related to the covid complications

Keywords: long covid-19 retrospective study artificial intelligence mental health
outcome study of conventional steroids vs. steroids combined with mycopehnolate in newly diagnosed immune thrombocytopenia purpura.

Conditions: Immune Thrombocytopenia Purpura

Summary: immune thrombocytopenia purpura (itp) is an autoimmune condition delineated by humoral as well as cell mediated immune response against thrombocyte surface proteins gpiib/iiia receptors, affecting primary homeostasis leading to mucocutaneous bleeding.itp is characterized by platelet count \<100 x 109/l. the conventional line of treatment for newly diagnosed itp is steroids but significant disadvantages have been associated with long term use and a high risk of relapse when reducing the dose. the addition of mmf to the first line treatment of itp resulted in substantial response and a lower risk of refractory itp with decreased financial burden and improved outcome.

immune thrombocytopenia purpura (itp) is an acquired, immune-mediated disorder characterized by a severe decrease in peripheral thrombocyte count to less than 100 x 10⁹/l, leading to mucocutaneous bleeding. our primary objective is to evaluate the efficacy of adding mycophenolate mofetil (mmf) alongside steroids in the first-line treatment of itp, aiming for an enhanced therapeutic response, lower risk of refractory and chronic itp, reduced financial burden, and improved overall outcomes. the study aims to validate the efficacy and safety of mmf as a first-line treatment option for itp while reducing the economic burden and risk of relapse associated with the condition

Eligibility criteria:
inclusion requirements: • age: 5-60 years • number of plates: \<30x109 exclusion standards: pregnancy; lactation; hepatitis b and c; hiv-reactive individuals; and medication allergies

Keywords: itp mmf
gut hormones as mediators of different weight loss responses after roux-en-y gastric bypass

Conditions: Bariatric Surgery (Gastric Bypass); Severe Obesity

Summary: after gastric bypass, 10-20% of patients will obtain a suboptimal weight loss, often defined as \<50% of the excess body weight. exaggerated meal related secretion of gut hormones seem important for appetite reduction and subsequent weight loss after gastric bypass, however it is not clear whether different gut hormone responses are responsible for different postoperative weight loss responses. the purpose of the study is to investigate gut hormone secretion, vagal integrity and the effect of octreotide on ad libitum food intake in patients with suboptimal weight loss after gastric bypass and compare results to a matched group of gastric bypass operated patients with high postoperative weight loss but similar age, sex and preoperative bmi.


Eligibility criteria:
inclusion criteria: * uncomplicated primary roux-en-y gastric bypass \>12 months ago * postoperative weight loss of \>60%ebl or \<50%ebl. exclusion criteria: * inadequately treated thyroid disease * hemoglobin \<6.5 mm * pregnancy or breastfeeding
the effect of beta-glucan in non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: the purpose of this study is to determine how beta-glucan affects the immune system in subjects with non-small cell lung cancer.

beta-glucan (imucell wgp) is an over-the-counter dietary supplement that enhances the body's immune system. imucell wgp is extracted from food-grade baker's yeast, which is permitted for use in food by the u.s. food and drug administration (fda). studies in animals have shown that imucell wgp helps trigger white blood cells to destroy cancer cells. other animal studies combining imucell wgp with anti-cancer medications have shown greater tumor regression and tumor-free survival.

Eligibility criteria:
aim 2: inclusion criteria: * suspected or definitive diagnosis of non-small cell lung cancer (nsclc) * treatment naive or no treatment within 6 months prior to enrollment * able to swallow pills * eastern cooperative oncology group (ecog) performance status of 0 to 3 * absolute neutrophil count (anc) at least 1500/microl * able to understand and willing to sign a written informed consent document exclusion criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements aim 3: inclusion criteria: * resectable non-small cell lung cancer (nsclc), as determined by a thoracic surgeon * treatment naive * able to swallow pills * eastern cooperative oncology group (ecog) performance status of 0 to 2 * must be an operative candidate * absolute neutrophil count (anc) at least 1500/microl * able to understand and willing to sign a written informed consent document exclusion criteria: * history of hypersensitivity reactions attributed to beta-glucan * currently receiving continuous corticosteroids or other ongoing immunosuppressive therapy * presence of an uncontrolled intercurrent illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Keywords: nsclc
the ambient light multiple myeloma study

Conditions: Multiple Myeloma

Summary: the aim of this multi-site randomized control trial will be is to assess the impact systematic lighting on circadian rhythm entrainment, inflammation, neutropenic fever and symptom burden among multiple myeloma patients undergoing autologous stem cell transplantation. to achieve this aim, 200 multiple myeloma patients will receive one of two different light-treatments that are designed to promote circadian rhythm alignment. while receiving these light treatments, participants' sleep efficiency, urine melatonin levels, blood inflammatory cytokine levels and symptoms will be assessed over a 2-month period.

individuals undergoing autologous stem cell transplant (asct) experience major transplant-related complications including elevated symptom burden, high rates of neutropenic fever, and increases in inflammatory cytokines. these transplant-related complications are augmented by circadian rhythms disruption (crd), which leads to misalignment between melatonin levels and sleep times. since light is a strong synchronizer of circadian rhythms, the proposed multi-site randomized controlled trial (rct) will investigate whether lighting designed to deliver circadian effective light that promotes circadian alignment, will: 1) promote higher nighttime melatonin levels and better nighttime sleep, 2) reduce pro-inflammatory cytokines, 3) lower rates of neutropenic fever and 4) improve symptom burden in cancer patients undergoing autologous stem cell transplant. hospital rooms for patients undergoing inpatient autologous stem cell transplant at the mount sinai medical center (msmc) and at the memorial sloan kettering cancer center (mskcc)) will be retrofitted to install 1 of 2 lighting interventions, either circadian-effective (intervention) and circadian-ineffective (comparison) ambient light that may improve sleep. 1-2 weeks and no more than 2 months prior to transplant, participants will be given an actiwatch, daysimeter (personal light meter), sleep logs, questionnaires, and a urine collection kit to assess melatonin. one blood sample for cytokine analyses will be collected during one of the hospital visits prior to transplant. blood draws are always done in the morning and always at a similar time for the same individual. the same outcomes (questionnaires, actiwatch, daysimeter, urine samples, blood samples) will be collected during transplant period and once, four weeks after engraftment.

Eligibility criteria:
inclusion criteria: * multiple myeloma diagnosis * scheduled to undergo their first autologous stem cell transplant procedure. * 21years or older * able to provide informed consent. * english-language proficient exclusion criteria: * previous autologous stem cell transplant procedure * pregnancy * eye diseases which limit the ability of light to be processed * secondary cancer diagnosis within the last 5 years * severe sleep disorders * history of bipolar disorder or manic episodes * severe psychological impairment * previous use of light therapy * active infection including covid-19 infection
bacterial metallophores in the diagnosis of acute pyelonephritis

Conditions: Acute Pyelonephritis; Complicated Urinary Tract Infection

Summary: the project aims to investigate bacterial metallophores as potential diagnostic markers of acute pyelonephritis and complicated urinary tract infections. these secondary metabolites are excreted by pathogenic microorganims in the course of infection for the uptake of iron and other metallic ions from the host. they are species-specific and can be detected in body fluids (including urine) by mass spectrometry. the potential contribution of this project is a culture-independent method for the diagnosis of the causative microbiological agent.

acute pyelonephritis (ap) is a clinical syndrome characterized by fever, chills, nausea vomiting and costovertebral angle tenderness, bacteriuria and pyuria. the underlying pathophysiology is based on the presence of microbes in the renal parenchyma which may progress to sepsis. complicated urinary tract infection (cuti) is one accompanied by abnormalities of the urinary tract or host factors which make the eradication of the infection difficult. the most common etiological agents include gram-negative enteric rods, i.e. e. coli, klebsiella pneumoniae; and enterococcus spp. empirical antibiotic treatment should be targeted once culture and sensitivity results become available. this usually takes 24-48 hours, occasionally even 72 hours. inadequate antibiotic treatment leads to higher mortality if the etiological agent is of a multi-drug resistant phenotype. metallophores are a major virulence factor of bacterial pathogens. these are chelating molecules secreted by the microbe for the uptake of iron, copper, and other metals from the host. e.g., siderophores aim at fe3+ ions removal from the host protein molecules; the complex then adheres to specific extracellular receptors on the microbial cell and is internalized. yersiniabactin is another metallophore which binds copper. proteomic analysis using mass spectrometry has been used in the detection of biomarkers for several pathological conditions: renal failure, post-transplant nephropathy, various malignancies etc. metallophores can be detected by mass spectrometry.

Eligibility criteria:
inclusion criteria: * in-patient with clinical signs and symptoms of ap/cuti or out-patient with clinical signs and symptoms of acute uncomplicated pyelonephritis or in-patient with no clinical signs of uti and a negative standard urine culture result exclusion criteria: * inability to consent

Keywords: metallophores mass spectrometry acute pyelonephritis complicated urinary tract infection siderophores yersiniabactin
international registry study of neutral lipid storage disease (nlsd) / triglyceride deposit cardiomyovasculopathy (tgcv) and related diseases

Conditions: Neutral Lipid Storage Disease

Summary: this study aims to understand the state of onset of nlsd(neutral lipid storage disease) / tgcv(triglyceride deposit cardiovasculopathy) worldwide, background information of affected patients, and natural history of the disease, as well as exploring the prognostic factors and assessing the efficacy of disease-specific treatment.

since nlsd is a rare disease, its clinical manifestation and clinical course have not been sufficiently clarified. also, the number of patients in each country is limited. as such, it is considered difficult to fully investigate this disease without international collaboration. therefore, we have established the international registry of nlsd / tgcv. also, all patients with jordans' anomaly of peripheral polymorphonuclear leukocytes are established as the subjects of entry when starting the registry, to allow entry of patients with nlsd due to genes other than mutations of atgl and cgi-58 genes. time perspective:this study is both prospective (registering patients who are diagnosed with nlsd / tgcv) and retrospective (registering only the medical record of previous patients).

Eligibility criteria:
inclusion criteria: * patients who are diagnosed with nlsd / tgcv exclusion criteria: * none

Keywords: jordans anomaly neutral lipid storage disease triglyceride deposit cardiovasculopathy atgl gene cgi-58 gene primary triglyceride deposit cardiomyovasculopathy (tgcv) neutral lipid storage disease with myopathy (nlsd-m)
f&p toffee full face mask clinical trial, nz, 2020

Conditions: Positive Airway Pressure Therapy; Obstructive Sleep Apnea

Summary: this will be a prospective, multi-arm, randomized, and non-blinded clinical trial designed to evaluate the performance, comfort, and usability of the toffee full face mask amongst participants who have been prescribed pap therapy by a physician. this clinical trial will take place across three investigation sites with a sample of 45 participants.

the purpose of this clinical investigation was to evaluate the performance, comfort and ease of use of the f\&p toffee full face mask. the clinical investigation took place across three sites in order to recruit the required number of participants. the clinical investigation tested the mask on 44 participants, who were currently using a full face mask for pap therapy. this was a non-randomized non-blinded single intervention study. informed consent was gathered from the 44 participants before demographic and baseline measurements were recorded. participants were issued an appropriate fitting toffee full face mask for the two week at home trial. after two weeks the participants returned the masks. at this visit device data was downloaded and participant questionnaires were completed.

Eligibility criteria:
inclusion criteria: * persons who are ≥ 22 years of age * persons who weigh ≥ 66 lbs (30 kgs) * persons who have been prescribed pap (apap, bpap or cpap) therapy by a physician * persons who are compliant with pap therapy for ≥ 4 hours per night for 70% of nights for at least two weeks prior to enrolment in the trial * persons who are currently using a full face mask * persons who have an ipap pressure of \< 30 cmh2o * persons who currently use a pap therapy device with data recording capabilities * persons who are fluent in spoken and written english * persons who possess the capacity to provide informed consent exclusion criteria: * persons who are intolerant to pap therapy * persons who are required to use pap therapy for more than 12 hours per day or for extensive periods other than sleep or naps * persons using nasal or nasal pillows masks * persons who possess, or suffer from, anatomical or physiological conditions which make pap therapy inappropriate * persons who are pregnant or think they may be pregnant * persons who use a pap therapy machine for the delivery of medicines, except supplemental o2 * persons who currently have cold or flu like symptoms at the time of recruitment * persons who have tested positive for covid-19 within the previous 28 days prior to enrolment